SCLC
-
June 16, 2016
Lung Cancer Highlights from ASCO 2016
Emma Shtivelman, PhDThis year, the Annual Meeting of the American Society of Clinical Oncology (ASCO) did not produce any truly groundbreaking revelations about new treatments for lung cancer. However, researchers did report quite a few positive findings, and some disappointing ones.
-
December 10, 2015
New Promising Drugs for Small Cell Lung Cancer
Emma Shtivelman, PhDAny type of advanced lung cancer is bad news, but a diagnosis of small cell lung cancer (SCLC) is a particularly grim one to receive. About 30 years have passed since any new treatments for SCLC were developed, and patients’ responses to standard chemotherapy with etoposide and cisplatin are short-lived. Hopefully, this will change soon.
-
June 11, 2015
Small Cell Lung Cancer at ASCO: Some Welcome News
Emma Shtivelman, PhDSmall cell lung cancer (SCLC) is a fatal disease that has not seen new drug approvals for the last 17 years. Considering the relative success of ‘immune checkpoint inhibitors’ in non-small cell lung cancer (NSCLC), it is not surprising that several abstracts recently presented at the 2015 American Society of Clinical Oncology (ASCO) annual meeting were devoted to clinical trials testing these trendy, immune… Read more »